Christine Codding, MD
Rheumatology · Oklahoma City, OKNPI 1811968399
Payments from drug & device makers
Across 1,063 payments — averaging $2637.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1M
- Eli Lilly$470K
- Novartis$352K
- GSK$269K
- Gilead$159K
- Amgen$149K
- plus $373K from 19 others
Across 22 payments — averaging $6816.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$149K
- Eli Lilly$704
What the payments were for
- Food & beverage$7,56898%
- Education$1162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 449 | $1,031,852 |
| Eli Lilly | 30 | $469,699 |
| Novartis | 41 | $352,486 |
| GSK | 125 | $268,724 |
| Gilead | 30 | $158,846 |
| Amgen(2 entities) | 77 | $148,759 |
| Pfizer | 53 | $143,779 |
| E.r. Squibb & Sons, L.L.C. | 63 | $113,280 |
| Janssen Research & Development, LLC | 16 | $83,103 |
| UCB SA | 6 | $14,959 |
| Bristol Myers Squibb | 4 | $6,042 |
| Sandoz | 2 | $4,683 |
| Regeneron | 2 | $4,669 |
| UCB, Inc. | 41 | $849 |
| Johnson & Johnson | 52 | $778 |
| AstraZeneca | 30 | $595 |
| Genentech USA, Inc. | 15 | $215 |
| Boehringer Ingelheim | 7 | $149 |
| Lilly USA, LLC | 6 | $94 |
| Fresenius Kabi USA, LLC | 4 | $89 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Sanofi | 3 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Tonix Medicines, Inc. | 2 | $34 |
| Forte Bio-pharma LLC | 1 | $16 |
How this compares
$2,803,825 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 51 | $327,866 |
| Humira PenAdalimumab | 33 | $221,272 |
| Humira(Cf) PenAdalimumab | 25 | $170,581 |
| Enbrel SureclickEtanercept | 20 | $147,257 |
| HumiraAdalimumab | 22 | $143,056 |
| Humira(Cf)Adalimumab | 13 | $84,530 |
| Orencia ClickjectAbatacept | 11 | $84,289 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 183 | $5,097 |
| Hydroxychloroquine Sulfate | 143 | $3,653 |
| Celecoxib | 172 | $3,424 |
| MethotrexateMethotrexate Sodium | 165 | $3,148 |
| Febuxostat | 23 | $3,104 |
| Cevimeline Hcl | 20 | $2,603 |
| Pregabalin | 85 | $1,415 |
| Cyclobenzaprine Hcl | 117 | $1,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira, Humira(Cf) | $1,031,852 | $555,45286 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Oklahoma City
- Latisha HeinlenOklahoma City$1.9M
- Cristina ArriensOklahoma City$1.8M
- Joan MerrillOklahoma City$1.8M
- Mohammad KhanOklahoma City$999K
- Fahed HamadehOklahoma City$321K
- William SchnitzOklahoma City$290K
- Michael PickrellOklahoma City$163K
- John GoetzingerOklahoma City$38K
- Judith JamesOklahoma City$18K
- Robert ArthurOklahoma City$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.